Roche NimbleGen said today that genomic services provider Ambry Genetics has become a certified service provider for the NimbleGen SeqCap EZ Exome workflow.

Ambry, based in Aliso Viejo, Calif., will provide target enrichment services using SeqCap EZ Human Exome combined with next-generation sequencing services.

The SeqCap EZ Exome technology uses a single tube of stable DNA oligos to capture all exons in solution in a simple, scalable workflow, and contains 2.1 million empirically optimized DNA probes, according to Roche NimbleGen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.